# Signals Article: Putative Target P23582 for Heart Failure with Preserved Ejection Fraction
Background
Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome characterized by the heart's inability to fill properly, despite a normal ejection fraction. It accounts for nearly half of all heart failure cases and poses significant challenges in treatment due to its heterogeneous nature and limited therapeutic options. Identifying novel targets for HFpEF could lead to improved treatment strategies and patient outcomes.
Data-mining rationale
In a recent reanalysis effort, UniProt entry P23582 was identified as a putative target for HFpEF. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200126062, GDS:200121576, GDS:200108904, GDS:200111351, and GDS:200086569. Although P23582 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing P23582 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of P23582's potential as a target for HFpEF. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of P23582 as a target for HFpEF, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of HFpEF. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of P23582. If validated, assessing the druggability of P23582 via DGIdb and ChEMBL will be crucial for potential therapeutic development.